Organigram (TSE:OGI) Sets New 1-Year Low – Here’s Why

Posted by on May 19th, 2026

Organigram Holdings Inc. (TSE:OGI – Get Free Report)’s stock price reached a new 52-week low on Tuesday . The company traded as low as C$1.44 and last traded at C$1.44, with a volume of 94564 shares changing hands. The stock had previously closed at C$1.48.

Wall Street Analyst Weigh In

OGI has been the topic of a number of research analyst reports. Canaccord Genuity Group set a C$3.00 price objective on shares of Organigram and gave the stock a “buy” rating in a research note on Tuesday, January 27th. ATB Cormark Capital Markets lowered Organigram from a “strong-buy” rating to a “moderate buy” rating and dropped their target price for the stock from C$3.50 to C$3.25 in a report on Wednesday, February 11th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Organigram presently has a consensus rating of “Buy” and a consensus target price of C$3.13.

View Our Latest Report on Organigram

Organigram Stock Performance

The company has a market cap of C$203.92 million, a price-to-earnings ratio of -6.78, a PEG ratio of 0.42 and a beta of 1.72. The company has a debt-to-equity ratio of 2.20, a quick ratio of 2.62 and a current ratio of 2.82. The firm’s 50 day simple moving average is C$1.89 and its 200-day simple moving average is C$2.09.

Insider Buying and Selling at Organigram

In other news, Director Donald Geoffrey Machum sold 17,929 shares of Organigram stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of C$1.86, for a total transaction of C$33,347.94. Following the sale, the director owned 1,125 shares of the company’s stock, valued at approximately C$2,092.50. The trade was a 94.10% decrease in their position. Over the last 90 days, insiders have sold 76,647 shares of company stock worth $142,753. Insiders own 31.32% of the company’s stock.

Organigram Company Profile

(Get Free Report)

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.

Featured Articles

Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.